United Therapeutics (NASDAQ:UTHR) Director Sells $500,010.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $500.01, for a total value of $500,010.00. Following the transaction, the director owned 4,190 shares in the company, valued at $2,095,041.90. This trade represents a 19.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher Causey also recently made the following trade(s):

• On Tuesday, January 6th, Christopher Causey sold 1,000 shares of United Therapeutics stock. The stock was sold at an average price of $510.00, for a total transaction of $510,000.00.

United Therapeutics Stock Up 0.2%

UTHR opened at $503.69 on Thursday. The firm’s fifty day simple moving average is $482.44 and its two-hundred day simple moving average is $399.49. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The company has a market cap of $21.69 billion, a price-to-earnings ratio of 19.09, a PEG ratio of 2.61 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the previous year, the company earned $6.39 earnings per share. The company’s quarterly revenue was up 6.8% on a year-over-year basis. On average, research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst upgrades and raised price targets reinforce bullish outlook (consensus “Moderate Buy” and ~$505–509 consensus targets); several firms have lifted targets and reiterated buys, supporting demand. MarketBeat UTHR coverage
• Positive Sentiment: Recent quarterly results: EPS beat estimates ($7.16 vs. $6.89) with a high net margin (~40.7%) and ROE near 19%, underscoring strong profitability that investors favor. Earnings summary
• Positive Sentiment: Institutional ownership remains very high (~94%) and some funds increased positions recently, which can support price stability and amplify analyst-driven buying. Institutional holdings
• Neutral Sentiment: Sector comparison piece highlights UTHR vs. Zoetis (ZTS) for value investors — useful for positioning but not an immediate catalyst. Zacks comparison article
• Neutral Sentiment: Market write-ups (e.g., Yahoo Finance) discuss UTHR’s attractive financial prospects; informative for longer-term investors but not an immediate price driver. Yahoo Finance analysis
• Negative Sentiment: Significant insider selling by COO Michael Benkowitz: large block sales on Jan. 5 totaling tens of thousands of shares (multiple filings; combined value in the millions), which can be viewed negatively by the market. Benko witz SEC filing
• Negative Sentiment: Director-level sales: Christopher Causey sold 1,000 shares (around $500 avg), and Jan Malcolm sold multiple small lots (50 shares each recently). Repeated director sales may create near-term selling pressure or signal portfolio rebalancing. Causey SEC filing Malcolm SEC filing

Analyst Ratings Changes

A number of analysts have recently issued reports on UTHR shares. UBS Group lifted their price target on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright raised their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Royal Bank Of Canada increased their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $509.50.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the period. Invesco Ltd. raised its position in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the period. Darwin Global Management Ltd. acquired a new position in United Therapeutics in the third quarter valued at approximately $317,617,000. Assetmark Inc. grew its position in United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after acquiring an additional 197,384 shares during the period. Finally, Norges Bank purchased a new position in United Therapeutics in the second quarter worth approximately $136,453,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.